Organization – Page 14

Lantheus’ Phase 3 SPLASH Trial Results: 177Lu-PNT2002 Shows Promise but May Not Overtake Pluvicto

12 months ago talkbio0Tagged Congress (U.S. Legislature), ESMO, Lantheus, Phase 3 SPLASH, Pluvicto, PSMA, PSMA-positive metastatic castration-resistant prostate cancer

Lantheus, Phase 3 SPLASH Trial, 177Lu-PNT2002, PSMA-positive metastatic castration-resistant prostate cancer, ESMO Congress 2024, Pluvicto

ESMO 2024: IO Biotech’s IO102-IO103 Vaccine in Combination with Pembrolizumab Shows Promising Results in Head and Neck Cancer

12 months ago talkbio0Tagged biotech, Cancer of Neck, Congress (U.S. Legislature), ESMO, Immunotherapy, Io satellite, IO102-IO103, Keytruda, pembrolizumab, Therapeutic Cancer Vaccine

IO Biotech, IO102-IO103, Pembrolizumab (Keytruda), Head and Neck Cancer, ESMO Congress 2024, Therapeutic Cancer Vaccine, Immunotherapy

KEYTRUDA (Pembrolizumab) Plus Chemoradiotherapy Reduces Mortality Risk by 33% in High-Risk Locally Advanced Cervical Cancer

12 months ago talkbio0Tagged Chemoradiotherapy, Congress, Congress (U.S. Legislature), high-risk, Keytruda, Locally, Malignant tumor of cervix, Overall Survival, pembrolizumab

KEYTRUDA (pembrolizumab), Chemoradiotherapy (CRT), High-risk locally advanced cervical cancer, Overall survival (OS), European Society for Medical Oncology (ESMO) Congress 2024

BIOSECURE Act Clears House Hurdle, Heads to Senate for Vote on Restricting Chinese Biotech Ties

1 year ago talkbio0Tagged BIOSECURE, Biotech Companies, Biotechnology, Chinese Language, Drug Industry, drug supply chain, innovation, National Security, Risk, Senate, United States, US House of Representatives, Voting

BIOSECURE Act, House of Representatives, Senate Vote, Chinese Biotech Companies, National Security Risks, U.S. Pharmaceutical Industry, Biotechnology Innovation, Drug Supply Chain

European Court Suspends EC’s Decision to Revoke Ocaliva’s Marketing Authorization

1 year ago talkbio0Tagged Advanz Pharma, authorization, Biliary Cholangitis, court, Decision, EC, European (ethnic group), Ocaliva, Primary Biliary Cholangitis

Ocaliva, European Court, EC decision, marketing authorization, primary biliary cholangitis, PBC, Advanz Pharma

Unveiling the Future of Biotech: Top 11 Startups to Watch in 2024

1 year ago talkbio0Tagged biotech, biotech startups, Biotechnology, Industry, innovation, trends qualifier

Biotech startups, Top biotech companies, Biotechnology industry, Emerging biotech trends, Biotech innovation, Biotech awards

The Post-Chevron Regulatory Landscape: Implications for the FDA and Healthcare Industry

1 year ago talkbio0Tagged Administrative procedure, Boards (medical device), Chevron Deference, Corner Post, court, Federal Reserve System, Governors, Healthcare Industry, judicial, Landscapes, Legal, Loper Bright Enterprises, Raimondo, regulatory, Supreme, United States Food and Drug Administration

Chevron deference, FDA, regulatory landscape, healthcare industry, Supreme Court ruling, Loper Bright Enterprises v. Raimondo, Corner Post, Inc. v. Board of Governors of the Federal Reserve System, Administrative Procedure Act (APA), judicial scrutiny, legal challenges, regulatory implications.